Lebrikizumab Improved Skin Signs, Quality of Life, and Showed High Levels of Patient Satisfaction in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis and Skin of Color

Abstract

Introduction: Lebrikizumab improved signs and symptoms in patients with skin of color (SoC) and moderate-to-severe atopic dermatitis (AD) after 16 weeks of treatment in ADmirable (NCT05372419), an open-label, Phase 3b clinical trial. Here we report 16-week quality of life (QoL) response and patient satisfaction results in this underrepresented patient population, as well as skin response and QoL response achieved for patients mostly/completely satisfied with treatment.

Methods: At baseline and Week 2, patients received 500-mg lebrikizumab loading doses followed by 250-mg every 2 weeks through Week 16. Concomitant topical therapy was allowed. Patients receiving protocol-defined rescue therapy were discontinued. Key eligibility criteria included: ≥12 years of age, self-reported race other than White, Fitzpatrick Phototype IV-VI, and moderate-to-severe AD. Skin response was assessed using Eczema Area and Severity Index (EASI) and QoL response was assessed using Dermatology Life Quality Index (DLQI). Patients reported satisfaction on the treatment’s ability to treat their AD by responding not satisfied, slightly satisfied, somewhat satisfied, mostly satisfied, or completely satisfied. Endpoints are summarized as observed data. The analysis was descriptive based on all observed data.

Results: At baseline, patients (N=90) had a mean (standard deviation [SD]) EASI of 26.4 (12.2), and n=77 had DLQI of 13.2 (7.4). Patients self-reported their race as Black/African American (77.8%), Asian (11.1%), American Indian/Alaskan Native (6.7%), and Native Hawaiian or Other Pacific Islander (4.4%). Patients had Fitzpatrick Phototypes of IV (43.3%), V (24.4%), and VI (32.2%). At Week 16, 71.7% (43/60) of patients achieved ≥4-point improvement from baseline in DLQI, 57.4% (39/68) achieved DLQI ≤5, and 29.4% (20/68) achieved DLQI 0,1. The mean percentage improvement in DLQI from baseline to Week 16 was 52.7% (n=66). In total, 62.8% (49/78) of patients were mostly/completely satisfied with treatment, while 37.2% (29/78) were somewhat, slightly or not satisfied. Of these 29 patients, 6 (7.7%) were not satisfied with treatment. For EASI 75 Week 16-responders, 74.1% (40/54) were mostly/completely satisfied with treatment and 71.4% (25/35) of EASI 90 responders were mostly/completely satisfied. In terms of QoL, 69.8% (30/43) of patients who achieved ≥4-point improvement from baseline in DLQI were mostly/completely satisfied with treatment, 76.9% (30/39) of DLQI ≤5 responders and 85.0% (17/20) of DLQI 0,1 responders were mostly/completely satisfied.

Conclusion: Lebrikizumab treatment showed improved QoL and high rates of patient-reported treatment satisfaction in SoC patients with moderate-to-severe AD. Patients treated with lebrikizumab who achieved high rates of skin clearance and QoL improvements reported the highest levels of treatment satisfaction.